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urement of hope and 639 abstracts on the measurement of psychological func-
tion in cancer were screened to identify publications focusing on the development 
of psychological instruments. In some cases, an article describing a promising 
instrument was selected and then used to identify the original validation study 
which was then substituted as the article selected for full text review. 16 measures 
with a hope focus or hope-specific items were identified for further review and 9 
measures of positive psychological constructs developed for use in the context of 
cancer were identified for further review. ConClusions: Positive psychological 
constructs factor into cancer treatment and symptom remission. Measurement of 
these domains is an important component of treatment selection and outcomes 
assessment. However, reliable and valid assessment of hope and related constructs 
depends on the availability of psychometrically sound instruments developed for 
this context of use. The present study demonstrates that while much work has 
been done in research settings to develop such measures, there is still a need for 
further refinement and development of these tools so that they are fit for use in a 
regulated research context.
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objeCtives: Overall aim of this study is to evaluate acceptability and usability of 
the Quality of Life-Portal (QOL-Portal), developed for breast cancer patients. The 
portal is designed for assessing information needs and patient’s QOL and enhanc-
ing patient education as well as health literacy. Methods: Software development 
has been done in close collaboration with a multidisciplinary group of healthcare 
professionals following an Extreme Programming approach. This means that soft-
ware development was based on an stepwise process that included the evaluation 
of individual components of the portal by healthcare professionals and subsequent 
adaptation in accordance with the provided feedback. Currently, we are conduct-
ing semi-structured interviews in breast cancer patients to collect information 
on acceptability and usability of the QOL-Portal. The main evaluation criteria are 
divided into usability (e.g. possible problems with web-access, user-friendliness and 
satisfaction) and content (e.g. understandability of information and of graphical 
questionnaire presentation). Results: Software development has been completed 
and resulted in an online QOL portal for breast cancer patients. Based on feedback 
from healthcare professionals we developed several components for the portal: an 
information module to enhance patients’ condition and treatment related knowl-
edge, health literacy, a symptom monitoring tool based on the EORTC questionnaires 
(allowing assessments in the hospital and at home), and a basic set of self-help 
interventions. In addition, the portal provides graphical feedback on the QOL results 
to patients themselves. Preliminary results from the ongoing patient interviews will 
be presented at the conference. ConClusions: QOL-Portals are gaining importance 
as they allow routine symptom assessment and provide important information to 
patients and medical alike. We have developed key components for the portal which 
undergo further adaption and improvement based on feedback from healthcare 
professionals and patients. In a next step, we will evaluate the impact of the portal 
on patients’ QOL.
PCN244
HeAltH relAteD QuAlity of life of CAregivers AND PAtieNts treAteD 
for metAstAtiC NoN-smAll Cell luNg CANCer (NsClC) WitH orAl 
viNorelbiNe
Linnet H1, Hansen O2, Meldgaard P3, Berdeaux G4, Mercier F5
1Herning Hospital, Herning, Denmark, 2Odense hospital, Odense, Denmark, 3Hospital Aarthus, 
Arthus, Denmark, 4Pierre Fabre, Boulogne Billancourt, France, 5STAT PROCESS, Paris, France
objeCtives: Oral chemotherapy was developed to reduce in-patient stays while 
providing the same level of efficacy and safety. This study assessed the health-
related quality of life (HRQoL) of patients treated with oral vinorelbine for metastatic 
NSCLC and their caregivers. Methods: This longitudinal survey assesses 2 visits 
documenting the second and third chemotherapy cycles. Patients had metastatic 
NSCLC and received oral vinorelbine (day 1 and 8 of 3-week cycles) and carboplatin 
(day 1). Baseline measures included demographics, anamnesis, co-morbidities and 
current treatment. SF-12 was reported at the end of each cycle, on the patients 
and interestingly on the caregivers. Results: Three Danish centers included 45 
patients: median age: 66.9 y.o., 53.3% were male. Performance status (ECOG) was 
0: 33.3%; 1: 51.1%; 2+: 15.6%. Main reason for choosing oral vinorelbine was con-
venience. Caregivers, mainly spouses (76.7%), were 57.8 y.o. No major change on 
SF-12 scores was reported between cycle 2 and 3. Physical summary scores (PCS) of 
patients (37.0-38.6, respectively cycle 2 and 3) were lower than those of caregivers 
(52.9-53.4) and general population (44). Mental summary scores (MCS) of patients 
(47.7-44.2) and caregivers (46.2-44.6) were much lower than those one of a popula-
tion of same age (patient: 52; caregiver: 51). The most affected patient scores were 
physical functioning (40.4), role physical (40.1), vitality (37.2). Social functioning (SF) 
was similarly high in patients and caregivers (76.9 vs. 78.9, patient vs. caregiver) 
while mental health of both patients and caregivers were lower (66.7 vs. 65.5) than 
SF. ConClusions: Metastatic NSCLC deeply affects patients’ HRQoL as measured 
by a generic instrument, both on MCS and PCS. Caregivers’ HRQoL is also affected, 
mainly on MCS. Patients receiving oral vinorelbine plus carboplatin and their car-
egivers maintain a good level of social functioning.
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with the use of a single approach (such as a single centre), (iii) the health state of 
the participant, and (iv) the burden on site staff affecting recruitment. The protocol 
addresses issue (i) by describing effectiveness in terms of time to need for new 
treatment rather than disease progression as well as cognitive debriefing; issues 
ii & iv using a broad spectrum of recruitment methods; (iii) minimising patient 
burden. ConClusions: The development of this protocol has been informed by 
lessons learnt from previous research. An analysis of the issues identified as limita-
tions in previous studies in collecting patient preference data allows improvements 
in protocol design.
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objeCtives: Patient-reported outcomes (PRO) provide a more comprehensive pic-
ture of patients’ quality of life than do mere physicians’ ratings. Electronic data 
collection of PRO offers several advantages and allows assessments at patients’ 
homes as well. This study reports on patients’ internet use, their attitudes towards 
electronic and web-based PRO assessment (clinic-ePRO and home-ePRO) and the 
feasibility of these two assessment modes. Methods: At the Medical University 
of Innsbruck and Kufstein County Hospital, cancer patients who participated in 
clinic-ePRO/home-ePRO were asked to complete a comprehensive evaluation form 
on their internet usage, attitudes towards and the feasibility of routine clinic-
ePRO/home-ePRO with the Computer-based Health Evaluation System (CHES) 
software. Results: In total, 158 patients completed the evaluation form. Most 
patients expressed willingness to complete routine clinic-ePRO (92.3%)/home-
ePRO (70%) assessments in the future and to discuss such data with attending 
physicians (82.2%). The CHES software for home-ePRO was preferred over phone 
interviews by 95.7% of patients and 72.7% experienced it as easy to use. Only a few 
minor suggestions for improvement were made. Overall satisfaction with home-
ePRO was high with an average rating of 9.1 points (range 5-10 points). However, 
there became an age bias apparent, as participating patients were approximately 
ten years younger than those refusing clinic-ePRO/home-ePRO. ConClusions: 
The use of clinic-ePRO/home-ePRO was in general shown to be feasible and well 
accepted. However, to be more inclusive in the implementation of clinic-ePRO/
home-ePRO, educational programs concerning their particular benefit in oncology 
practice potentially could enhance patients’ attitudes towards, and consequently 
their acceptance of and compliance with electronic PRO assessments.
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objeCtives: To investigate the effects of adverse events on quality of life (QOL) scores 
during adjuvant chemotherapy for breast cancer patients. Methods: We analyzed 
the QOL scores assessed by EQ-5D and the worst grades of adverse events assessed 
by the National Cancer Institute - Common Toxicity Criteria(NCI-CTC) Version 2.0 
collected from a national multicenter phase III randomized clinical trial: National 
Surgical Adjuvant Study of Breast Cancer-02 (N-SAS BC 02), which compared two 
types of taxane-containing chemotherapy, as an approved sub analysis numbered 
CSP-HOR22. A linear regression model was constructed with change in EQ-5D score 
as an objective variable, calculated as the worst scores minus the baseline (before 
chemotherapy) scores, and the incidences of adverse events as independent vari-
ables, set as binary variables regardless of grade. Results: From 300 participants, 
250 complete series of data of EQ-5D scores and adverse events were extracted. The 
average baseline EQ-5D score was 0.798. The average of worst EQ-5D scores for each 
participant during chemotherapy was 0.720 and the average change in EQ-5D score 
was -0.078, with a range of -0.619 to +0.464. Although QOL deteriorated in 140 patients, 
it improved in 54 patients. Seventeen adverse events were selected as independent 
variables excluding rare ones. The following three coefficients of the regression model 
were significant; edema: -0.056 (p= 0.03), phlebitis: 0.068 (p= 0.01), and sensory nerve 
disturbance: -0.084 (p< 0.01), and these results are equivalent to simple linear regres-
sion models for each factor. ConClusions: Cases of QOL improvement events may 
have reduced the model’s descriptive power and caused a positive coefficient value. 
Since patients treated with taxane-containing chemotherapy often suffer sensory 
nerve disturbance as well as edema for a longer period, even after the termination 
of chemotherapy, clinicians should provide selective care to avoid deterioration of 
patients’ QOL.
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objeCtives: To understand the ways in which hope and related constructs are 
applied and measured in the context of healthcare, especially in patients with 
cancer. Targeted literature reviews were conducted in two areas: (1) Psychological 
assessments measuring hope, and (2) Measures of psychological function in 
cancer-related care, including well-being and other positive psychological con-
structs. Methods: To better understand the scope of psychological assessments 
developed and currently in use to measure hope and related positive psychological 
constructs in the context of healthcare, a targeted review of the published literature 
was undertaken. MEDLINE and PsychINFO database searches were conducted for 
publications in English in the past 5 years. Results: 876 abstracts on the meas-
